On December 28, 2021, Texas Children’s Hospital and Baylor College of Medicine announced that CORBEVAX™, a protein sub-unit COVID-19 Vaccine, whose technology was created and engineered at its the hospital’s Center for Vaccine Development (CVD), has received Emergency Use Authorization (EUA) approval from the Drugs Controller General of India (DCGI) to launch in India with other underserved countries to follow. Dubbed “The World’s COVID-19 Vaccine,” this vaccine uses a traditional recombinant protein-based technology that will enable its production at large scales making it widely accessible to inoculate the global population. The initial construct and production process of the vaccine antigen was developed at Texas Children’s Hospital CVD, led by co-directors Drs. Maria Elena Bottazzi and Peter Hotez and in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialization team, to Hyderabad-based vaccine and pharmaceutical company Biological E. Limited (BE).